Literature DB >> 11973432

Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein.

Paul Cumming1, Dean F Wong, Nicholas Gillings, John Hilton, Ursula Scheffel, Albert Gjedde.   

Abstract

According to the ternary complex model of G-protein linkage to receptors, agonists increase the affinity of the receptors for the G protein. The model predicts that an endogenous agonist's constant of inhibition toward an agonist radioligand is lower than that toward an antagonistic radioligand. The authors hypothesized that competition from endogenous dopamine in striatum of living mice should have a greater effect on the binding of the D2,3 partial agonist N-[3H]propylnorapomorphine than on the binding of the D2,3 antagonist [(11)C]raclopride. The baseline binding potential (pB(0)), defined as the ratio of bound-to-unbound ligand in the absence of competition from endogenous dopamine, was simultaneously measured in mouse striatum for [(11)C]raclopride (pB(0) = 8.5) and N-[(3)H]propylnorapomorphine (p'B(0) = 5.3). The baseline was established by treatment with alpha-methyl-p-tyrosine and reserpine. Relative to these baseline values in saline-treated mice, the pB of N-[(3)H]propylnorapomorphine decreased 52% whereas the pB of [(11)C]raclopride decreased only 30%, indicating greater sensitivity of the former compound to inhibition by synaptic dopamine. Furthermore, amphetamine decreased the pB of N-[(3)H]propylnorapomorphine to a greater extent (73%) than that of [(11)C]raclopride (43%) relative to the reserpine condition. For both radioligands, the occupancy of the dopamine receptors by endogenous agonist obeyed Michaelis-Menten kinetics over a wide range of agonist concentrations established by the pharmacologic treatments. The apparent inhibition constant of endogenous dopamine depended on the dopamine occupancy and decreased to a value 1.66 times greater for N-[(3)H]propylnorapomorphine than for [(11)C]raclopride at its highest occupancies. The results are consistent with the hypothesis that agonist binding is more sensitive than antagonist binding to competition from endogenous dopamine. Therefore, dopamine agonist ligands may be superior to benzamide antagonist ligands for the estimation of dopamine receptor occupancy by endogenous synaptic dopamine. The analysis of the effect of dopamine occupancy on the inhibition of N-[(3)H]propylnorapomorphine binding indicated a limited supply of G protein with a maximum ternary complex fraction of 40% of maximum agonist binding capacity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11973432     DOI: 10.1097/00004647-200205000-00011

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  19 in total

1.  Dopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding.

Authors:  Mette Skinbjerg; Nicholas Seneca; Jeih-San Liow; Jinsoo Hong; David Weinshenker; Victor W Pike; Christer Halldin; David R Sibley; Robert B Innis
Journal:  Synapse       Date:  2010-09       Impact factor: 2.562

2.  Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors.

Authors:  Mette Skinbjerg; Yoon Namkung; Christer Halldin; Robert B Innis; David R Sibley
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

3.  Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system.

Authors:  Masaki Tokunaga; Nicholas Seneca; Ryong-Moon Shin; Jun Maeda; Shigeru Obayashi; Takashi Okauchi; Yuji Nagai; Ming-Rong Zhang; Ryuji Nakao; Hiroshi Ito; Robert B Innis; Christer Halldin; Kazutoshi Suzuki; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 4.  Testing for radioligand sensitivity to endogenous neurotransmitter release.

Authors:  Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 5.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

Review 6.  Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction?

Authors:  Mette Skinbjerg; David R Sibley; Jonathan A Javitch; Anissa Abi-Dargham
Journal:  Biochem Pharmacol       Date:  2011-09-16       Impact factor: 5.858

7.  Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release.

Authors:  Patrick Neil McCormick; Nathalie Ginovart; Alan A Wilson
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

8.  In vivo serotonin-sensitive binding of [11C]CUMI-101: a serotonin 1A receptor agonist positron emission tomography radiotracer.

Authors:  Matthew S Milak; Alin J Severance; Jaya Prabhakaran; J S Dileep Kumar; Vattoly J Majo; R Todd Ogden; J John Mann; Ramin V Parsey
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-23       Impact factor: 6.200

9.  Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET.

Authors:  Matthew S Milak; Alin J Severance; R Todd Ogden; Jaya Prabhakaran; J S Dileep Kumar; Vattoly J Majo; J John Mann; Ramin V Parsey
Journal:  J Nucl Med       Date:  2008-03-14       Impact factor: 10.057

10.  D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model.

Authors:  Mette Skinbjerg; Jeih-San Liow; Nicholas Seneca; Jinsoo Hong; Shuiyu Lu; Annika Thorsell; Markus Heilig; Victor W Pike; Christer Halldin; David R Sibley; Robert B Innis
Journal:  Neuroimage       Date:  2010-01-22       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.